Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Ferrant E, Wierda WG, Munugalavadla V, Yu T, Wang MH, Byrd JC.
Sharman JP, et al. Among authors: karlsson k.
Leukemia. 2022 Apr;36(4):1171-1175. doi: 10.1038/s41375-021-01485-x. Epub 2022 Jan 1.
Leukemia. 2022.
PMID: 34974526
Free PMC article.
No abstract available.